Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

Representatives from academia, industry, regulatory agencies, and patient groups
convened in March 2019 with the primary goal of developing agreement on chronic hepatitis …

Engineering chimeric antigen receptors (CAR) or T cell receptors (TCR) helps create
disease-specific T cells for targeted therapy, but the cost and rigor associated with …

Chronic hepatitis B virus (HBV) infection is a global public health challenge on the same
scale as tuberculosis, HIV, and malaria. The International Coalition to Eliminate HBV (ICE …

Hepatitis B virus (HBV) infection remains a major public health concern worldwide with
about 257 million individuals chronically infected. Current therapies can effectively control …

Viral hepatitis, secondary to infection with hepatitis A, B, C, D, and E viruses, are a major
public health problem and an important cause of morbidity and mortality. Despite the huge …

The liver is an immunologically tolerant organ that is uniquely equipped to limit
hypersensitivity to food-derived antigens and bacterial products through the portal vein and …

A great effort of research has been devoted in the last few years to developing new anti-HBV
therapies of finite duration that also provide effective sustained control of virus replication …

Fewer than 1% of chronic hepatitis B virus infections per year are cured with antiviral
treatment. This creates a need for long-term treatment, which poses challenges for patients …

Multiple new therapeutic approaches are currently being developed to achieve sustained,
off-treatment suppression of HBV, a persistent hepatotropic infection that kills~ 2,000 people …